8-((2S,5R)-4-((2,2-difluorobenzo[d][1,3]dioxol-5-yl)methyl)-2,5-dimethylpiperazin-1-yl)-5-methyl-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile

ID: ALA4646970

Chembl Id: CHEMBL4646970

PubChem CID: 146529452

Max Phase: Preclinical

Molecular Formula: C24H23F2N5O3

Molecular Weight: 467.48

Molecule Type: Unknown

Associated Items:

Names and Identifiers

Canonical SMILES:  C[C@@H]1CN(c2cc(=O)n(C)c3ccc(C#N)nc23)[C@@H](C)CN1Cc1ccc2c(c1)OC(F)(F)O2

Standard InChI:  InChI=1S/C24H23F2N5O3/c1-14-12-31(19-9-22(32)29(3)18-6-5-17(10-27)28-23(18)19)15(2)11-30(14)13-16-4-7-20-21(8-16)34-24(25,26)33-20/h4-9,14-15H,11-13H2,1-3H3/t14-,15+/m1/s1

Standard InChI Key:  ITSXSYKMRJAHCY-CABCVRRESA-N

Alternative Forms

  1. Parent:

    ALA4646970

    ---

Associated Targets(Human)

DGKA Tbio Diacylglycerol kinase alpha (73 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DGKZ Tchem Diacylglycerol kinase zeta (13 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
DGKA Tbio Diacylglycerol kinase alpha/zeta (14 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: UnknownTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 467.48Molecular Weight (Monoisotopic): 467.1769AlogP: 3.23#Rotatable Bonds: 3
Polar Surface Area: 83.62Molecular Species: NEUTRALHBA: 8HBD:
#RO5 Violations: HBA (Lipinski): 8HBD (Lipinski): #RO5 Violations (Lipinski):
CX Acidic pKa: CX Basic pKa: 7.06CX LogP: 3.72CX LogD: 3.55
Aromatic Rings: 3Heavy Atoms: 34QED Weighted: 0.58Np Likeness Score: -0.87

References

1. Abdel-Magid AF..  (2020)  Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinases Alpha and Zeta.,  11  (6): [PMID:32550982] [10.1021/acsmedchemlett.0c00118]

Source